Identification
- Summary
Periciazine is a phenothiazine used with other medications to treat aggressiveness, impulsiveness, and hostility associated with psychiatric conditions such as schizophrenia.
- Brand Names
- Neuleptil
- Generic Name
- Periciazine
- DrugBank Accession Number
- DB01608
- Background
Periciazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects and an action on the extrapyramidal system. It is used as an adjunctive medication in some psychotic patients, for the control of residual prevailing hostility, impulsiveness and aggressiveness. Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade.
- Type
- Small Molecule
- Groups
- Approved, Investigational
- Structure
Structure for Periciazine (DB01608)
- Weight
- Average: 365.492
Monoisotopic: 365.156183063 - Chemical Formula
- C21H23N3OS
- Synonyms
- 10-(3-(4-Hydroxypiperidino)propyl)phenothiazine-2-carbonitrile
- 2-Cyano-10-(3-(4-hydroxy-1-piperidyl)propyl)phenothiazine
- 2-Cyano-10-(3-(4-hydroxypiperidino)propyl)phenothiazine
- Cyano-3 ((hydroxy-4 piperidyl-1)-3 propyl)-10 phenothiazine
- Periciazina
- Periciazine
- Périciazine
- Periciazinum
- Pericyazine
- Piperocyanomazine
- Propericiazine
- External IDs
- RP 8909
- RP-8909
- SKF 20716
- SKF-20716
Pharmacology
- Indication
For use as adjunctive medication in some psychotic patients. Propericiazine (Pericyazine)is used for the control of residual prevailing hostility, impulsiveness and aggressiveness.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
- Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.- Pharmacodynamics
Pericyazine is a phenothiazine of the piperidine group. It has been shown to reduce pathologic arousal and affective tension in some psychotic patients, while the symptoms of abnormal mental integration are relatively unaffected. It is a sedative phenothiazine with weak antipsychotic properties. It also has adrenolytic, anticholinergic, metabolic and endocrine effects, and an action on the extrapyramidal system.
- Mechanism of action
Pericyazine, like other phenothiazines, is presumed to act principally in the subcortical areas, by producing what has been described as a central adrenergic blockade of the alpha adrenergic receptors as well as antagonism of the D(1) dopamine receptor.
Target Actions Organism ADopamine D1 receptor antagonistHumans AAlpha-2A adrenergic receptor antagonistHumans UAlpha-1B adrenergic receptor antagonistHumans UAndrogen receptor Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
In milder cases of phenothiazine overdosage the patient may be agitated, delirious and confused. Frequently he is lethargic or in a comatose state. Twitching, dystonic movements or convulsions may be present and hypotension, cardiovascular collapse, arrhythmias and hypothermia might be observed.
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your software1,2-Benzodiazepine The risk or severity of adverse effects can be increased when Periciazine is combined with 1,2-Benzodiazepine. Acebutolol The serum concentration of Acebutolol can be increased when it is combined with Periciazine. Aceclofenac The risk or severity of hypertension can be increased when Periciazine is combined with Aceclofenac. Acemetacin The risk or severity of hypertension can be increased when Periciazine is combined with Acemetacin. Acetazolamide The risk or severity of adverse effects can be increased when Acetazolamide is combined with Periciazine. Acetohexamide The therapeutic efficacy of Acetohexamide can be decreased when used in combination with Periciazine. Acetophenazine The risk or severity of adverse effects can be increased when Acetophenazine is combined with Periciazine. Acetylsalicylic acid The risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Periciazine. Aclidinium Periciazine may increase the central nervous system depressant (CNS depressant) activities of Aclidinium. Agomelatine The risk or severity of adverse effects can be increased when Periciazine is combined with Agomelatine. 
Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Avoid alcohol.
- Take with food. Food reduces irritation.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- International/Other Brands
- Neulactil / Neuleptil
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Neuleptil Capsule 5 mg Oral Erfa Canada 2012 Inc 1969-12-31 Not applicable Canada 
Neuleptil Capsule 10 mg Oral Erfa Canada 2012 Inc 1969-12-31 Not applicable Canada Neuleptil Capsule 20 mg Oral Erfa Canada 2012 Inc 1976-12-31 Not applicable Canada Neuleptil Solution / drops 10 mg / mL Oral Erfa Canada 2012 Inc 1976-12-31 Not applicable Canada
Categories
- ATC Codes
- N05AC01 — Periciazine
- Drug Categories
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Adrenergic Antagonists
- Agents that produce hypertension
- Antipsychotic Agents
- Antipsychotic Agents (First Generation [Typical])
- Central Nervous System Depressants
- Dopamine Antagonists
- Heterocyclic Compounds, Fused-Ring
- Nervous System
- Neurotoxic agents
- Phenothiazines
- Phenothiazines With Piperidine Structure
- Psycholeptics
- Sulfur Compounds
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Benzothiazines
- Sub Class
- Phenothiazines
- Direct Parent
- Phenothiazines
- Alternative Parents
- Alkyldiarylamines / Diarylthioethers / Piperidines / Benzenoids / 1,4-thiazines / Trialkylamines / Secondary alcohols / Nitriles / Azacyclic compounds / Organopnictogen compounds show 1 more
- Substituents
- Alcohol / Alkyldiarylamine / Amine / Aromatic heteropolycyclic compound / Aryl thioether / Azacycle / Benzenoid / Carbonitrile / Diarylthioether / Hydrocarbon derivative show 14 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- phenothiazines, nitrile, hydroxypiperidine (CHEBI:31981)
- Affected organisms
- Humans and other mammals
Chemical Identifiers
- UNII
- 3405M6FD73
- CAS number
- 2622-26-6
- InChI Key
- LUALIOATIOESLM-UHFFFAOYSA-N
- InChI
- InChI=1S/C21H23N3OS/c22-15-16-6-7-21-19(14-16)24(18-4-1-2-5-20(18)26-21)11-3-10-23-12-8-17(25)9-13-23/h1-2,4-7,14,17,25H,3,8-13H2
- IUPAC Name
- 10-[3-(4-hydroxypiperidin-1-yl)propyl]-10H-phenothiazine-2-carbonitrile
- SMILES
- OC1CCN(CCCN2C3=CC=CC=C3SC3=C2C=C(C=C3)C#N)CC1
References
- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0015546
- KEGG Drug
- D01485
- PubChem Compound
- 4747
- PubChem Substance
- 46505085
- ChemSpider
- 4585
- BindingDB
- 50346422
- 8766
- ChEBI
- 31981
- ChEMBL
- CHEMBL251940
- ZINC
- ZINC000000538159
- Therapeutic Targets Database
- DAP000413
- PharmGKB
- PA164781043
- Wikipedia
- Propericiazine
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 3 Unknown Status Treatment Psychosis Nos/Other 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Capsule Oral 10 mg Capsule Oral 20 mg Capsule Oral 5 mg Solution / drops Oral 10 mg / mL Solution / drops Oral 2 G/100ML Tablet 10 MG Tablet 5 MG - Prices
Unit description Cost Unit Neuleptil 20 mg Capsule 0.52USD capsule Neuleptil 10 mg/ml Drops 0.41USD ml Neuleptil 10 mg Capsule 0.34USD capsule Neuleptil 5 mg Capsule 0.21USD capsule DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 116-117 °C PhysProp water solubility 38 mg/L (at 37 °C) YALKOWSKY,SH & DANNENFELSER,RM (1992) logP 3.52 HANSCH,C ET AL. (1995) logS -3.98 ADME Research, USCD - Predicted Properties
Property Value Source Water Solubility 0.059 mg/mL ALOGPS logP 3.78 ALOGPS logP 3.11 ChemAxon logS -3.8 ALOGPS pKa (Strongest Acidic) 15.18 ChemAxon pKa (Strongest Basic) 8.37 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 1 ChemAxon Polar Surface Area 50.5 Å2 ChemAxon Rotatable Bond Count 4 ChemAxon Refractivity 108.4 m3·mol-1 ChemAxon Polarizability 40.87 Å3 ChemAxon Number of Rings 4 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule No ChemAxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.9747 Blood Brain Barrier + 0.9691 Caco-2 permeable + 0.5608 P-glycoprotein substrate Substrate 0.6582 P-glycoprotein inhibitor I Inhibitor 0.8072 P-glycoprotein inhibitor II Inhibitor 0.6046 Renal organic cation transporter Inhibitor 0.6545 CYP450 2C9 substrate Non-substrate 0.7657 CYP450 2D6 substrate Substrate 0.6233 CYP450 3A4 substrate Non-substrate 0.6064 CYP450 1A2 substrate Inhibitor 0.6843 CYP450 2C9 inhibitor Non-inhibitor 0.8852 CYP450 2D6 inhibitor Inhibitor 0.6558 CYP450 2C19 inhibitor Non-inhibitor 0.8539 CYP450 3A4 inhibitor Non-inhibitor 0.8952 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.7203 Ames test Non AMES toxic 0.6802 Carcinogenicity Non-carcinogens 0.9537 Biodegradation Not ready biodegradable 1.0 Rat acute toxicity 2.9345 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.7341 hERG inhibition (predictor II) Inhibitor 0.6604
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted GC-MS Spectrum - GC-MS Predicted GC-MS Not Available GC-MS Spectrum - EI-B GC-MS splash10-03xu-7932000000-163720fa7ee8e5adf313 GC-MS Spectrum - EI-B GC-MS splash10-03di-4931000000-bc6eaf361b17af48a30f Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- G-protein coupled amine receptor activity
- Specific Function
- Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
- Gene Name
- DRD1
- Uniprot ID
- P21728
- Uniprot Name
- D(1A) dopamine receptor
- Molecular Weight
- 49292.765 Da
References
- Kanba S, Suzuki E, Nomura S, Nakaki T, Yagi G, Asai M, Richelson E: Affinity of neuroleptics for D1 receptor of human brain striatum. J Psychiatry Neurosci. 1994 Jul;19(4):265-9. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Yes
- Actions
- Antagonist
- General Function
- Thioesterase binding
- Specific Function
- Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
- Gene Name
- ADRA2A
- Uniprot ID
- P08913
- Uniprot Name
- Alpha-2A adrenergic receptor
- Molecular Weight
- 48956.275 Da
References
- Tsukamoto T, Asakura M, Hirata N, Imafuku J, Matsui H, Hasegawa K: Interaction of neuroleptics and antidepressants with rat brain alpha 2-receptors: a possible relationship between alpha 2-receptor antagonism and antidepressant action. Biol Psychiatry. 1984 Sep;19(9):1283-91. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- Actions
- Antagonist
- General Function
- Protein heterodimerization activity
- Specific Function
- This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
- Gene Name
- ADRA1B
- Uniprot ID
- P35368
- Uniprot Name
- Alpha-1B adrenergic receptor
- Molecular Weight
- 56835.375 Da
References
- Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
- Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
- Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [Article]
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Zinc ion binding
- Specific Function
- Steroid hormone receptors are ligand-activated transcription factors that regulate eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Transcription ...
- Gene Name
- AR
- Uniprot ID
- P10275
- Uniprot Name
- Androgen receptor
- Molecular Weight
- 98987.9 Da
References
- Bisson WH, Cheltsov AV, Bruey-Sedano N, Lin B, Chen J, Goldberger N, May LT, Christopoulos A, Dalton JT, Sexton PM, Zhang XK, Abagyan R: Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs. Proc Natl Acad Sci U S A. 2007 Jul 17;104(29):11927-32. Epub 2007 Jul 2. [Article]
Drug created at August 29, 2007 18:52 / Updated at January 27, 2022 17:28